Table 3.
Validation of VIREA using detectable tenofovir concentrations in vaginal fluid at matching study visits
| VIREA outcome | Tenofovir detected in vaginal fluid | ||
|---|---|---|---|
| No | Yes | Total study visits | |
| ≤50% ‘appeared used’ | 32 (86.5%) | 5(13.5%) | 37 |
| >50% ‘appeared used’ | 141(41.7%) | 197 (58.3%) | 338 |
| Total | 173 | 202 | 375 |
Fisher’s exact p<0.0001